How much funding has Neuron23 raised?

Neuron23 has raised $310.0M in total funding, most recently a Series D round.

Who are Neuron23's investors?

Neuron23's investors include Westlake Village BioPartners, Blue Owl Capital, SoftBank, Redmile Group, Kleiner Perkins.

Where is Neuron23 headquartered?

Neuron23 is headquartered in South San Francisco, California, United States.

What industry is Neuron23 in?

Neuron23 operates in Biotech, Drug Discovery, Genomics, Healthcare.

Neuron23

Changing the future of Parkinson's disease.

South San Francisco, United States · Founded 2018 · $310.0M raised

Headquarters: South San Francisco, California
Employees: 11–50
Founded: 2018
Business Model: B2B

Website: neuron23.com
Total Funding: $310.0M
Last Round: $96.5M Series DJun 2025
Rounds: 4

About

Neuron23 is a clinical-stage biotechnology company combining human genetics and data science to develop precision medicines for Parkinson's disease. Its lead program targets LRRK2, a genetic driver of Parkinson's, using machine learning and functional genomics to identify and match patients to therapies. The company was founded in 2018 by a team of drug hunters, geneticists, and neuroscientists.

Summary

Neuron23 is a Biotech company based in South San Francisco, United States, founded in 2018. It has raised $310.0M in total across 4 rounds, most recently a $96.5M Series D round in Jun 2025. Investors include Westlake Village BioPartners, Blue Owl Capital and SoftBank.

LinkedIn X (Twitter)